Apolipoprotein-mimetic Peptides: Current and Future Prospectives.

Apolipoprotein-mimetic peptides, mimicking the biological properties of apolipoproteins, have shown beneficial properties against various diseases (central and peripheral diseases) and have emerged as potential candidates for their treatments. Progress has been made from first-generation to second-generation apolipoprotein-mimetic peptides. Understanding these peptides from the first generation to the second generation is discussed in this review.

ApoE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation.

Background: Peptides derived from the apolipoproteins (apo-mimetic peptides) have emerged as a potential candidate for the treatment of various inflammatory conditions. Our previous results have shown that peptides derived from human apolipoprotein-E interact with various pro-inflammatory lipids and inhibit their inflammatory functions in cellular assays.

Objective: In this study, two apoE-derived peptides were selected to investigate their antiinflammatory and anti-oxidative effects in streptozotocin-induced diabetic model of inflammation and oxidative stress.

Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function.

Apolipoprotein-derived peptides are promising candidates for the treatment of various inflammatory conditions. The beneficial effects of these peptides are based on multiple mechanisms; prominent among them being high-affinity binding to pro-inflammatory oxidized phospholipids (Ox-PLs) and facilitating their sequestration/metabolism/clearance in the body. This indicates that peptides which can bind exclusively to Ox-PLs without recognizing normal, non-oxidized phospholipids (non-Ox-PLs) will be more potent anti-inflammatory agent than that of the peptides that bind to both Ox-PLs and non-Ox-PLs.

Apolipoprotein E derived peptides inhibit the pro-inflammatory effect of lysophosphatidylcholine.

Apolipoprotein-derived peptides have emerged as a potential candidate for the treatment of various inflammatory disease conditions. These peptides bind to pro-inflammatory lipids and inhibit their inflammatory functions. Lysophosphatidylcholine (LPC) is a potent pro-inflammatory lipid and increased level of circulating LPC plays a major role in various acute and chronic inflammatory conditions.

Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs.

Apolipoprotein-derived peptides are promising candidates for the treatment of various inflammatory conditions and the main mechanism proposed for the protective action of these peptides includes binding to pro-inflammatory lipid mediators with high affinity and facilitating their sequestration/metabolism/clearance in the body. Molecules that act as pro-inflammatory lipid mediators differ considerably in their molecular structures, chemical compositions and physicochemical properties. Importance of the properties of pro-inflammatory lipid mediators on the biological activity of apolipoprotein-derived peptides has not been studied in detail.

Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides.

Apolipoprotein-derived peptides have emerged as a promising candidate for the treatment of various inflammatory disease conditions. Multiple mechanisms have been proposed to explain the beneficiary effects of these peptides and prominent among them being high-affinity binding of peptides to pro-inflammatory lipids and facilitating their sequestration/metabolism/clearance in the body. Pro-inflammatory lipids differ considerably in their molecular structures, chemical compositions and physicochemical properties.

Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E.

Apolipoprotein E (apoE) plays a major role in the transport and metabolism of lipid by acting as a ligand for low density lipoprotein-receptors. The amphipathic helical regions of its C-terminal domain are necessary for the lipoprotein binding and assembly of nascent lipoprotein particles. Lipoproteins in the plasma are known to possess a net negative charge, determined by both its protein and lipid components, which regulates the metabolism of lipoproteins.